Evidence map›Paper›PMID 32432092›Full record

ReviewFrontiers in bioengineering and biotechnology2020

PLGA-Based Drug Delivery Systems for Remotely Triggered Cancer Therapeutic and Diagnostic Applications.

Xue Shen, Tingting Li, Xiaoxue Xie, Yi Feng, Zhongyuan Chen, Hong Yang, Chunhui Wu, Shengqi Deng, Yiyao Liu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Drug repurposing for cancer therapy.Signal transduction and targeted therapy · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xue ShenSichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, China.
Tingting LiSchool of Life Sciences and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Xiaoxue XieSchool of Life Sciences and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Yi FengSchool of Life Sciences and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Zhongyuan ChenSchool of Life Sciences and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Hong YangSchool of Life Sciences and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Chunhui WuSchool of Life Sciences and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Shengqi DengSichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, China.
Yiyao LiuSchool of Life Sciences and Technology, University of Electronic Science and Technology of China, Chengdu, China.
University of Electronic Science and Technology of China · CNChengdu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intelligent drug delivery systems based on nanotechnology have been widely developed and investigated in the field of nanomedicine since they were able to maximize the therapeutic efficacy and minimize the undesirable adverse effects. Among a variety of organic or inorganic nanomaterials available to fabricate drug delivery systems (DDSs) for cancer therapy and diagnosis, poly(D,L-lactic-co-glycolic acid) (PLGA) has been extensively employed due to its biocompatibility and biodegradability. In this paper, we review the recent status of research on the application of PLGA-based drug delivery systems (DDSs) in remotely triggered cancer therapy and the strategies for tumor imaging provided by PLGA-based DDSs. We firstly discuss the employment of PLGA-based DDSs for remotely triggered cancer therapy, including photo-triggered, ultrasound-triggered, magnetic field-triggered, and radiofrequency-triggered cancer therapy. Photo-triggered cancer therapy involves photodynamic therapy (PDT), photothermal therapy (PTT), and photo-triggered chemotherapeutics release. Ultrasound-triggered cancer therapy involves high intensity focused ultrasound (HIFU) treatment, ultrasound-triggered chemotherapeutics release, and ultrasound-enhanced efficiency of gene transfection. The strategies which endows PLGA-based DDSs with imaging properties and the PLGA-based cancer theranostics are further discussed. Additionally, we also discuss the targeting strategies which provide PLGA-based DDSs with passive, active or magnetic tumor-targeting abilities. Numerous studies cited in our review demonstrate the great potential of PLGA-based DDSs as effective theranostic agent for cancer therapy and diagnosis.

Indexed as

imagingPLGA-based DDSsremotely triggered cancer therapytargetingtheranostics

Identifiers

PMID32432092
PMCPMC7214837
OpenAlexW3022410933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.